Physiologically Based Pharmacokinetic (PBPK) Modeling of Small Molecules: How Much Progress Have We Made?

Nina Isoherranen

Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington
Running Title Page

Running title: Progress in PBPK models

Address correspondence to: Nina Isoherranen, Department of Pharmaceutics, School of Pharmacy, University of Washington, Health Science Bldg., Box 357610, Seattle, Washington, USA 98195; phone: (206) 543-2517; email: ni2@uw.edu

Number of text pages: 30

Number of tables: 2

Number of figures: 2

Number of references: 94

Number of words in Abstract: 249

Number of words in Body of Manuscript: 7971

Keywords: in vitro to in vivo predictions, mechanistic models, physiologically based, pharmacokinetics, model verification

Abbreviations: CL, clearance; PBPK Physiologically based pharmacokinetic:
Abstract

Physiologically based pharmacokinetic (PBPK) models of small molecules have become mainstream in drug development and in academic research. The use of PBPK models is continuously expanding with the majority of work now focusing on predictions of drug-drug interactions, drug-disease interactions, and changes in drug disposition across lifespan. Recently, publications that use PBPK modeling to predict drug disposition during pregnancy and in organ impairment have increased reflecting the advances in incorporating diverse physiological changes into the models. Due to the expanding computational power and diversity of modeling platforms available, the complexity of PBPK models has also increased. Academic efforts have provided clear advances in better capturing human physiology in PBPK models and incorporating more complex mathematical concepts into PBPK models. Examples of such advances include the segregated gut model with a series of gut compartments allowing modeling of physiological blood flow distribution within an organ and zonation of metabolic enzymes, and series compartment liver models allowing simulations of hepatic clearance for high extraction drugs. Despite these advances in academic research, the progress in assessing model quality and defining model acceptance criteria based on the intended use of the models has not kept pace. This review suggests that awareness of the need for predefined criteria for model acceptance has increased but many manuscripts still lack description of scientific justification and/or rationale for chosen acceptance criteria. As artificial intelligence and machine learning approaches become more broadly accepted, these tools offer promise for development of comprehensive assessment for existing observed data and analysis of model performance.

Significance Statement
PBPK modeling has become a mainstream application in academic literature and is broadly used for predictions, analysis and evaluation of pharmacokinetic data. Many significant advances have been made in developing advanced PBPK models that better capture human physiology but oftentimes sufficient justification for the chosen model acceptance criterion and model structure is still missing. This review provides a summary of the current landscape of PBPK applications used and highlights the needs for advancing PBPK modeling science and training in academia.
Introduction

Physiologically based pharmacokinetic (PBPK) modeling is a computational technique that uses physiological information together with biochemical and physicochemical characteristics of the drug to simulate plasma, tissue and excreta concentrations as a function of time for drugs and their metabolites. All PBPK models consist of system components and drug specific components that are independent of each other. PBPK models can incorporate various levels of physiological complexity and drug elimination and distribution processes depending on the intended use and the level of knowledge of the characteristics of the drug. For example, a full body PBPK model will typically include majority of the defined organs in the body such as large distribution organs (muscle, skin, adipose, bone), main drug eliminating organs (liver, kidney, intestine), possible sites of drug administration (intestine, lung) and other organs of interest for drug distribution or action (heart, brain, pancreas, spleen). These tissue compartments are connected through the lungs via blood flow that includes venous and arterial compartments (Figure 1). In contrast, minimal PBPK models lump together many major organs or include a nonspecific distribution compartment (Jeong et al., 2022b; a), and typically incorporate only some, if any, organs of interest such as the liver, kidney or a target organ as individual organs (Figure 1). Depending on the research questions and intended use, the modeler can incorporate different types of organ models or levels of physiological information into the PBPK model leading to a great diversity and flexibility in the application of PBPK models. In addition, physiological models can be specific for a single organ and the relevant drug disposition processes in that organ, and used to only predict organ clearances. For example, a number of physiologically based models of the kidney have been developed (Neuhoff et al., 2013; Scotcher, Jones, Rostami-Hodjegan, et al., 2016; Huang and Isoherranen, 2018; Matsuzaki et al., 2019) to simulate renal clearance, and numerous
models exist for advanced modeling of oral formulations and intestinal absorption (Ahmad et al., 2020; Jamei et al., 2020; Wu and Li, 2023).

The use of PBPK modeling has increased continuously over the past 20 years (Sager et al., 2015; El-Khateeb et al., 2021). PBPK modeling has been routinely included in regulatory submissions for over a decade (Zhao et al., 2011; Christian Wagner, Pan, and Hsu, 2015; Christian Wagner, Pan, Hsu, et al., 2015; C Wagner et al., 2015; Luzon et al., 2017; Grimstein et al., 2019; Zhang et al., 2020; Jean et al., 2021), and is frequently reported in research applications published in scientific literature (Sager et al., 2015; El-Khateeb et al., 2021). PBPK modeling approaches have now become standard in assessment of drug-drug interaction risk (Shebley et al., 2018; El-Khateeb et al., 2021) and have been used extensively to predict absorption kinetics and formulation effects (Ahmad et al., 2020; Jamei et al., 2020; Wu and Li, 2023). They are also increasingly used to predict pharmacokinetic changes in specific populations (pregnant and lactating individuals, patients with renal or hepatic impairment) and across lifespan (pediatrics, geriatrics), and in exploring drug exposures at target site or specific organ pharmacokinetics-pharmacodynamics (PK-PD) (Sager et al., 2015; El-Khateeb et al., 2021). Numerous reviews have addressed the use of PBPK models in regulatory decision making (Zhao et al., 2011; C Wagner et al., 2015; Luzon et al., 2017; Grimstein et al., 2019; Zhang et al., 2020; Jean et al., 2021) and the reader is referred to these reviews and references therein for insight on how PBPK modeling is used in the context of model informed drug design (MIDD)(Madabushi et al., 2022). For industry applications, the IQ group and several industry consortia have provided extensive reviews of the use and application of PBPK modeling in drug discovery and development (Shebley et al., 2018; Hariparsad et al., 2022).

The current review is written from an academic perspective. It focuses on the progress made over the past decade in PBPK model development and use in research applications available in the
published literature, and summarizes the trends in model development, verification, and application workflows for different populations together with major advances made in developing more complex physiological models.

**PBPK Modeling Platforms and Data Availability**

The PBPK modeler has a choice between the use of existing, user friendly PBPK software packages with graphical user interfaces (SimCYP, GastroPlus, PK-Sim, GI-Sim, Simbiology) in which the model structure is typically *a priori* defined, or making their own custom models using various programming approaches (Matlab, R, Mobi within PK-Sim, ADAPT and others). The versatility in modeling platforms increases the need for advanced training in programming languages and techniques and in model assessment and evaluation in pharmaceutical sciences. While training expectations in population PK approaches and statistical analyses are fairly mature, the didactic training required for competency in PBPK modeling is less well defined and can still vary considerably from institution to institution. Due to the increasing availability of easy-to-use mathematical modeling software and the expanding computational power and speed, the use of PBPK modeling is continuously expanding to more complex model structures and applications. This increases the need for the modeler to possess in-depth mechanistic understanding of the underlying physiology and biochemistry of the developed PBPK models in addition to technical modeling expertise. Hence, academicians need to look into the future in terms of flexibility in curricula and training opportunities to prepare pharmaceutical sciences trainees to understand, use and advance PBPK modeling in a scientifically rigorous way. Similarly, funding agencies should assess whether the training currently provided across academic institutions is sufficient to ensure qualified workforce in this
area to address the needs of drug discovery and development and in clinical practice to improve patient outcomes.

The PBPK modeling packages include open and closed source applications, and there are variable levels of transparency between software applications to the underlying model code and mathematical assumptions made in model development (Aldibani et al., 2023; Rajput et al., 2023). Understanding the model structure and how different components in the model are connected is integral for assessing the validity of developed models for applications that expand the use of the model to predicting disposition in unstudied scenarios. Such understanding is also needed when comparing PBPK models developed for the same drug but using different software packages or when transferring models from one platform to another. For example, when simvastatin PBPK models developed using Simcyp or PK-Sim platforms were compared, the authors noted that the choice of the model development strategy was different for the two platforms resulting in different model input parameters but similar model performance (Prieto Garcia et al., 2022). This highlighted the need for in-depth knowledge of the PBPK modeling platform and model structure (Prieto Garcia et al., 2022).

There has been surprisingly little discussion in the scientific literature about the need for transparency in the underlying assumptions and construction of the models that are published regardless of whether the modeling platform is open or closed source. There is an increasing expectation that research become open (https://www.unesco.org/en/open-science) and the requirements for open science are increasing (McKiernan et al., 2016) With general data availability statements becoming commonplace, the lack of specific guidance on transparency and open access of PBPK models remains. At present there is no clear description of standards for research publications on making PBPK models publicly available and how to “Publicly share
data and materials via a trusted repository” (McKiernan et al., 2016). It has been recommended that “whenever it is feasible, the data, materials and analysis code used to generate the findings reported in one’s manuscript should be shared” (McKiernan et al., 2016) At present no publicly available trusted repository or database that would serve the community at large exist for PBPK models beyond databases that provide physiological parameters (Chang et al., 2021) or gene expression datasets (Cordes and Rapp, 2023). Most sharing of developed drug models occurs through proprietary databases of models developed for specific platforms and are restricted to user groups. As such the discussion and standards for reusability of models across platforms and users is still developing (Aldibani et al., 2023; Rajput et al., 2023).

A distinct gap in tools that would facilitate open science for PBPK modeling is the lack of converters available to export models from different closed source software applications to a common language or another software package that could be read and interpreted by broad community of users. Such applications are exemplary in the mass spectrometry and proteomics fields where it is a standard expectation that raw data generated by a commercial platform can be converted to a format generally readable by the scientific community who do not have access to the specific vendor software. The lack of open tools within PBPK community slows down science due to redundant model development and duplication of efforts, hinders progress in the field due to lack of open exchange of scientific solutions and limits collaborative efforts between users of different modeling platforms.

**Model development, applications, and verification**

Reports of the use of PBPK models in scientific literature have increased rapidly over the past ten years (Figure 2). When the published literature was systematically reviewed in 2015 using
the search terms “PBPK” and “Physiologically based pharmacokinetic model” a total of 366 PBPK-related articles were identified that included PBPK modeling of pharmaceutical agents in humans (Sager et al., 2015). A similar Pubmed search in July 2023 yielded 3,759 matches demonstrating the explosion in publications involving PBPK modeling. About 20% of these publications were identified as reviews or systematic reviews. Figure 2 shows the increase in publications mentioning PBPK over the past three decades. The trend observed is very similar to that reported by others (El-Khateeb et al., 2021).

The number of publications of PBPK models grew steadily between 2005 and 2018 but the number of publications per year has somewhat plateaued since 2018 regardless of the application of the PBPK model (Figure 2). It is possible that this plateau is related to the COVID-19 pandemic and does not reflect a longer-term trend. Future analyses will be needed to assess this trend. On the other hand, with PBPK modeling becoming a more mature field, it is also possible that the pace of advances in modeling has slowed, and some model development efforts have become standardized and no longer merit publication. As such, the number of publications should not be used as the sole indicator of how often PBPK modeling is used as part of a research program.

When the distribution of the applications of PBPK models in the published literature was evaluated in 2015 the most common application for PBPK models was drug-drug interaction predictions (Sager et al., 2015). This trend continued throughout the decade following that review with drug interactions remaining the most common application of PBPK models with about 2-3-fold increase in the number of publications in this area each year (Figure 2). Use of PBPK modeling for predicting age dependent changes in drug disposition in different pediatric populations (neonates, infants, young children, adolescents) has also remained an important
application with about 3-4 fold increase in yearly publications in this area. This reflects the early acceptance of PBPK for this application already reported in 2015 (Sager et al., 2015) and incorporation of PBPK modeling in drug development for pediatric populations (Freriksen et al., 2023). In comparison, the use of PBPK modeling for organ impairment, pharmacogenetics or pregnancy saw about a 5-fold increase in the publications considering these areas (Figure 2) even though these areas of application remain a minority of PBPK modeling applications. The increase in the use of PBPK for specific populations reflects the advancements made over the past decade in understanding the diverse physiological processes and biochemical changes in these populations. This emerging understanding allows mechanistic modeling and prediction of drug disposition in these populations.

In addition, they provide guidance on how to report PBPK models, and the recommendations from regulatory submissions can be adapted and refined for the scientific literature and research applications.

One of the recommended criteria for PBPK model use has been to report a predefined model acceptance criterion for the developed model (Jones et al., 2015). When publications of PBPK models were reviewed in 2015, it was, however, noted that only about half of the published models specified a criterion for model verification *a priori* (Sager et al., 2015). When these criteria were reported, most commonly a 2-fold range for an observed pharmacokinetic parameter in comparison to predicted was considered acceptable. Some papers also used a more stringent (25-30% range within observed mean parameter) criterion. For drug-drug interaction models a 2-fold criterion for predicted and observed DDI magnitude was often used with some authors opting for a more stringent 30% of the observed change. It was noted that the choice of these acceptance criteria was not clearly justified in the papers and did not match the types of drugs (narrow therapeutic index, P450 sensitive probes), and that overall criteria for model acceptance were inconsistent. Others have also shown that the 2-fold criterion may in some cases be too liberal and in some cases too stringent due to the observed variability in the drug disposition characteristics and due to the small study populations in the observed datasets (Abduljalil et al., 2014). Yet, the theory and statistical analyses for PBPK model acceptance criteria have remained relatively rigid over the past decade.

To evaluate whether model verification practices have changed since the review in 2015, a subset of published manuscripts describing PBPK models since 2015 were analyzed as a representative sample. To capture the most recent and up-to-date approaches the manuscripts published in 2022 were chosen for this evaluation. A Pubmed search of the PBPK models
published in humans for drugs during the year of 2022 yielded 382 published manuscripts. Of these, 71 were marked as reviews yielding a sample size of 316 manuscripts, a similar initial sample size as the 366 manuscripts identified overall for the 2015 analysis. These manuscripts were further reviewed for whether they specified the application of PBPK models reported and provided original PBPK model development yielding a dataset of 187 manuscripts. These manuscripts were then evaluated for the type of application, for the strategy of model development, model verification criteria and for the software used. As noted in the previous analysis as well, this sample size is likely an incomplete set of all the papers published for PBPK modeling in humans in 2022 but it is expected to represent adequately the use of PBPK models with the exception of absorption and formulation modeling which was not specifically searched for in the current review.

Approximately half of the models in 2022 were developed to simulate drug-drug interactions, a larger fraction than what was reported by others (El-Khateeb et al., 2021). Of these reports half addressed PBPK modeling of metabolic drug-drug interactions involving inhibition and induction of predominantly cytochrome P450 enzymes but also other metabolic enzymes. About 20% of the published models considered drug-drug interactions involving drug transporters such as OATPs and kidney transporters such as OATs and MATEs. The remaining third of the drug-drug interaction studies included modeling pH dependent drug absorption interactions, mixed mechanisms of drug-drug interactions and drug interactions involving pharmacological activity.

Interestingly, use of PBPK modeling to simulate drug disposition in pediatric populations remained a common application with ~14% of the applications focusing on pediatric populations. The use of PBPK models to simulate the disposition of monoclonal antibodies
remained somewhat rare accounting for ~5% of overall of the published papers. Many PBPK models (~10%) incorporated simulations of pharmacogenetic variation in the modeling approach. Ten (~5%) manuscripts described the application of PBPK modeling to pregnant populations to either predict drug disposition in the pregnant mother or to evaluate the fetal exposure and potential toxicokinetics in the fetus for the therapeutic agents. A total of 15 manuscripts (8%) were identified that described PBPK modeling in renal or hepatic impairment populations. Of these, eight were for renal impairment/chronic kidney disease populations, four for hepatic impairment/liver disease and three that included both organ impairment populations. Overall the distribution of applications was relatively similar to that described in 2015.

The use of PBPK modeling to predict drug disposition in populations with organ impairment (hepatic or renal impairment) is of special interest as organ impairment studies are often challenging to conduct, and the patients with organ impairment may be at increased risk of adverse events making dosage adjustment critical. Due to the complexity of multiple drug disposition mechanisms affected by organ impairment (altered liver or kidney blood flow, changes in protein binding, altered enzyme/transporter expression) the changes in drug disposition in different organ impairment scenarios can be difficult to predict using traditional static methods. **Table 1** summarizes the 14 manuscripts published for organ impairment populations in 2022. These studies used a variety of simulation platforms/programs. For the renal impairment population three of the studies were conducted using PK-Sim platform (C Wu *et al.*, 2022; Dubinsky *et al.*, 2022; Alsmadi and Alzughoul, 2023), three were conducted using Simcyp population simulator (Miao *et al.*, 2022; Wang and Chan, 2022b; a) and one using Gastroplus (Y Xu *et al.*, 2022). For hepatic impairment populations three of the studies were conducted using Simcyp (Watanabe *et al.*, 2022; X Wu *et al.*, 2022; Ladumor *et al.*, 2023) and one using PK-Sim (L Xu *et al.*, 2022).
For the studies that considered both RI and HI populations one used PK-Sim (Fan et al., 2022), one used Simcyp (Itohara et al., 2022) and one used Gastroplus (Zhao et al., 2022). This distribution of software packages differs somewhat from what was reported in 2015, perhaps unsurprisingly as software development is highly dynamic with new options becoming available frequently. One may also speculate that depending on the specific purpose of use of the developed model (Organ impairment, drug-drug interactions etc) certain software packages may be uniquely suited for such applications due to work and development that has been put into developing population models.

In terms of model acceptance criteria all but two (Fan et al., 2022; Miao et al., 2022) of the manuscripts listed a predefined model acceptance criterion in the manuscript. The manuscript by (Miao et al., 2022) was unique as this study tested prospective prediction of dorzagliatin disposition in renal impairment population using PBPK modeling and hence observed data was not available for the modeling exercise for the intended use. The frequency of reporting model acceptance criteria and defining these criteria prior to model development and verification shows a clear increase in the awareness on the importance of defining model acceptance criteria a priori when compared to the status of the field in 2015. However, the diversity of approaches adopted for model acceptance was somewhat surprising. In some cases a calculation of acceptance criterion based on observed variability in vivo was used, in some cases an AAFE, AFE or percent error cutoff was applied and some publications still used a 2-fold criterion (Table 1). As already noted in 2015 (Sager et al., 2015) the acceptance criterion was not matched to the therapeutic index or sensitivity of a substrate and the 2-fold criterion was used for some drugs and scenarios where this is clinically likely too lenient (Table 1). A notable advancement with PBPK models of organ impairment is the inclusion of studies that combine drug interactions with organ
impairment scenarios. These applications provide an illustration of the flexibility of PBPK modeling to evaluate complex scenarios and provide guidance in situations where clinical trials may be very challenging. Similarly, the application of PBPK-PD in organ impairment populations is an important advancement in the field.

Another area of interest for PBPK modeling is the use of PBPK models to explore drug disposition during pregnancy (Gaohua et al., 2012; Ke et al., 2012; Jing et al., 2017; Zhang and Unadkat, 2017; Zhang et al., 2017; Shum et al., 2021). There is a great need for reliable PBPK models to predict drug disposition during pregnancy as minority of the drugs given to pregnant women have ever been evaluated in pregnant women for PK or PD changes (Ke et al., 2014a, 2018; Abduljalil and Badhan, 2020). Hence drugs are often given to pregnant women off-label despite the fact that the drug treatment may be critical for the survival of the mom and the health of the developing fetus. It is well established that pharmacokinetics of drugs changes during pregnancy due to multiple processes (change in blood flows and GFR, altered protein binding and albumin concentrations, increased or decreased CYP expression in the liver) and that these changes can be dependent on gestational age (Isoherranen and Thummel, 2013; Ke et al., 2014b). As pregnant women are a sensitive population, studying all the drugs given to pregnant women and incorporating all the different gestational stages into clinical studies is practically and ethically impossible. PBPK modeling can provide much needed information on prioritizing specific studies in pregnant women and in directing dosage adjustments and selection of therapies based on predicted exposures. PBPK modeling also provides a unique opportunity to predict maternal-fetal disposition of drugs and fetal exposures to the drug of interest (Zhang and Unadkat, 2017; Zhang et al., 2017; Shum et al., 2021; Balhara et al., 2022). This is especially important and significant as sampling of drug concentrations from the fetal compartment is not possible across
gestation and simulations of the fetal exposures can provide extremely valuable information about the risks and benefits of drug treatment to the fetus.

A decade ago about 2% of the publications describing PBPK models addressed pregnancy as the target application (Sager et al., 2015). In the current analysis pregnancy modeling had increased. Of the 187 manuscripts published in 2022 that were reviewed ten (~5%) described the application of PBPK modeling to pregnant populations to either predict drug disposition in the pregnant mother or to evaluate the fetal exposure and potential toxicokinetics of the therapeutic agents in the fetus (Table 2). The majority (n=5) of the pregnancy PBPK models were constructed using Simcyp simulator (Abduljalil, Ning, et al., 2022; Abduljalil, Pansari, et al., 2022; Bukkems et al., 2022; Peng et al., 2022; Li and Xie, 2023), but other software packages such as R (n=2, Chang et al., 2022; Kapraun et al., 2022)), PK-Sim (n=2, Alsmadi, 2023; Liu et al., 2023)) and Gastroplus or combination of software platforms (Coppola et al., 2022) were also used. It is notable that R packages are particularly used for pregnancy modeling while none of the organ impairment applications used R. This is likely due to the toxicology applications and consideration within the pregnancy modeling and the broad use of R packages in the field of toxicokinetics. The review also revealed that all three major software packages, Simcyp, Gastroplus and PK-Sim include pregnancy models within the software package facilitating applications of PBPK modeling to predicting drug disposition during pregnancy, maternal-fetal distribution of drugs and potential toxicokinetics during pregnancy.

Within the pregnancy applications a variety of model acceptance criteria were used within and between the studies and majority of the studies defined model acceptance criteria in model development workflow (Table 2). Four studies stated that model performance was evaluated based on visual comparison of predicted and observed data (Abduljalil, Ning, et al., 2022;
Chang et al., 2022; Alsmadi, 2023; Liu et al., 2023), while one study assessed the correlation between predicted and observed data (Kapraun et al., 2022). Two studies used the 90% predictive interval as the range that observed data needed to be within (Alsmadi, 2023; Li and Xie, 2023) and one specified a visual comparison of the observed mean plasma concentration-time curve and the predicted 5-95th percentile (Coppola et al., 2022). Two of the papers (Abduljalil, Pansari, et al., 2022; Peng et al., 2022) specifically noted that the observed plasma concentration-time curve had to be within the 5th and 95th percentile of the simulated. Similarly two papers (Bukkems et al., 2022; Peng et al., 2022) established a stringent criteria for predicted pharmacokinetics parameters with 0.8-1.25 fold (bioequivalence) or 0.7-1.3-fold (narrow therapeutic index), respectively. The 2-fold range of pharmacokinetics parameters was also used in two studies (Li and Xie, 2023; Liu et al., 2023).

The pregnancy PBPK models included a diversity of verification datasets to assess model performance. Many of the pregnancy applications were based on previously developed PBPK models that had been already assessed for model performance in nonpregnant population (Table 2). The pregnancy modeling was then undertaken to evaluate either maternal-fetal distribution in which case umbilical vein to maternal plasma ratios were often used for model verification, or to define the maternal PK during pregnancy. Most of these models followed the generally recommended workflow where the drug model was verified in nonpregnant population prior to applying it to pregnant population. Taken together these models show the increasing trust in PBPK modeling in evaluating drug disposition during pregnancy. A notable advancement was the incorporation of the mechanistic kidney model into pregnancy PBPK modeling for renally cleared drugs (Abduljalil, Ning, et al., 2022; Abduljalil, Pansari, et al., 2022; Coppola et al., 2022; Li and Xie, 2023) although it was noted that limited information is available for physiological changes in
the kidney during pregnancy and for how transporter expression changes in the kidney during pregnancy. Several of the papers (Bukkems et al., 2022; Peng et al., 2022) also used either perfused placenta studies or mechanistic modeling of the placenta to better predict maternal-fetal distribution. Taken together this review shows significant advances over the past decade in the mechanistic PBPK modeling of drug disposition during pregnancy.

Different Model Structures and Approaches for Clearance Processes in PBPK models

All PBPK models make some underlying assumptions regarding the physiological processes that govern drug elimination and distribution. All models also simplify the overall complexity of the human body. As usage of PBPK models has increased there has been a parallel increase in development of more complex models that attempt to better capture clearance processes, distribution characteristic, intestinal absorption, and drug administration via inhalation or transdermal routes. However, the models can only be as good as the underlying knowledge of the physiology and physiological parameters that are incorporated into the models. As model complexity increases it is becoming apparent that the knowledge of human physiology that governs drug disposition is a limiting factor for model development. The heterogeneity of many diseases and the corresponding heterogeneity in physiological changes is not yet well incorporated into current PBPK modeling frameworks. Some well-known deficiencies include the lack of knowledge of precise transporter expression in the human kidney tubular epithelial cells rather than whole kidney in vivo, the localization of the transporters at different subsections of the kidney, and the lack of knowledge on how pH gradients and tubular flows are altered in the different sections of the kidney when urine pH or flow is altered or in chronic kidney disease (Scotcher, Jones, Posada, Rostami-Hodjegan, et al., 2016). Similarly, the physiological changes
associated with pregnancy such as changes in liver and kidney blood flow, intestinal mobility and transit time, gastric emptying and active uptake transport in the intestine have not been well characterized and limit further PBPK modeling in pregnancy. It is also noteworthy that the understanding of detailed physiological changes that occur in various cancers and different stages of cancer progression or during treatment is limited. Due to the challenges in conducting detailed pharmacokinetic studies in these patient populations coupled with the narrow therapeutic index of most treatments, PBPK modeling has the potential to greatly improve dosing regimen design and individualized therapy in cancer chemotherapy but better data is needed in the general physiology to advance the field.

Sensitivity analyses can be used to demonstrate that lack of such physiological knowledge has minimal impact on model performance in many cases. However, for drugs that have a high hepatic extraction ratio, such as THC or metoprolol for example, lack of knowledge about hepatic blood flow changes during pregnancy is a major challenge for modeling their disposition during pregnancy. Similarly, for drugs that have renal clearance that is sensitive to urine pH, the poor characterization on how pH gradients are established across the kidney during pregnancy or in disease states such as chronic kidney disease can confound model development. As such there is a continuous need for PBPK modelers to partner with scientists who can develop advanced tools of characterization of physiological processes and their alterations in disease states and apply these tools to practice in clinical research.

The incorporation of more complex PBPK models into commercial software platforms has lagged behind academic research advances. For example, at the time of this writing the segregated gut model (Pang et al., 2017, 2020; Noh and Pang, 2019) has not been incorporated into commercial software packages despite the fact that it allows modeling the route dependent
metabolism of drugs that are subject to significant gut extraction. Typically, PBPK modeler can choose between approaching absorption kinetics using simple first order absorption model that incorporates the absorption constant $k_a$ and the fraction absorbed as predefined parameters, or using a more complex model that is typically a further developed version of the original advanced compartmental absorption transit (ACAT) model (Yu and Amidon, 1999). The advanced absorption kinetic models include the advanced dissolution absorption metabolism (ADAM) model in Simcyp, the advanced compartmental absorption and transit (ACAT) model in GastroPlus and a series compartment model in GI-Sim. All of these allow predictions of oral bioavailability based on physicochemical drug characteristics and experimental permeability data of the drug (Sjögren et al., 2016). These models provide advanced ability to model drug absorption from the intestine in a segmented fashion. They can account for the differences in gut wall permeability between different regions, differences in pH across different regions of the intestine and the heterogenous expression and localization of metabolic enzymes and drug transporters in the intestine. Although these models generally have similar structures, the predictive performance of the different gastrointestinal drug absorption models can be quite different (Sjögren et al., 2016).

An important application of PBPK modeling and simulation of drug absorption and food effects (Tistaert et al., 2019; Riedmaier et al., 2020; Al Shoyaib et al., 2023). However, confidence in model predictions in this area is still moderate. A review of the literature and regulatory submissions suggested that PBPK modeling is typically used to attempt to predict food effects for BCS class II and IV drugs (Li et al., 2018). The reasoning for this was that BCS class I drugs typically are not subject to food effects and BCS class III drugs often involve transporters for absorption, an area for which food effects have not been mechanistically characterized (Li et al.,...
The authors noted that in half of the PBPK modeling cases assessed, food effects were predicted within 1.25-fold and 75% of the simulations were within 2-fold. Yet, the authors concluded that caution should be exercised in determining the performance of PBPK models in this area (Li et al., 2018). In a separate case study assessment from several pharmaceutical companies, it was suggested that for immediate release formulations of BCS class I and II compounds, PBPK modeling can be used to predict lack of food effect and positive food effect (Tistaert et al., 2019). However, it was noted that the absorption model for such applications should be well validated, fasted state PK should be available and the model should be validated for clinical data on a food effect before extrapolation to expanded food effect simulations. Surprisingly in a subsequent industry perspective publication (Riedmaier et al., 2020) BCS classification did not appear to affect the level of confidence in PBPK predictions of food effects. Majority of the food effects considered were predicted with high to moderate confidence leading to a recommendation to leverage PBPK modeling in assessment of food effects (Riedmaier et al., 2020). However, overall confidence in PBPK modeling of bioavailability, bioequivalence and food effects is still weaker than many other applications and subject to active research. In an FDA workshop regarding food effects and PBPK modeling, the topic of differences in input parameter values between software platforms was brought up and it was noted that there is a need for standardization on how data is generated in vitro to be used in PBPK modeling (Al Shoyaib et al., 2023). Recently PBPK modeling has also been expanded to model the drug-drug interactions resulting from acid reducing agents causing changes in gastric pH (Dong et al., 2020). This work suggested that such drug-drug interactions could be adequately predicted but further work is needed with modeling drugs which are affected significantly by changes in gastric pH.
The compartmental absorption models have been noted to result in many ordinary differential equations for which solutions are computationally facile (Nagar et al., 2017). As an alternative continuous absorption models have been developed (Willmann et al., 2004; Nagar et al., 2017). In these models physiological values such as surface area, pH and experimental velocities were incorporated into the model together with specific cellular characteristics of the enterocyte across the length of the intestine. Physicochemical characteristics governing the absorption of oral solutions and solid dosage forms were also incorporated and the oral absorption of a series of model drugs was well predicted. However, these continuous models are yet to be incorporated into commonly used PBPK software platforms.

A weakness of the currently commonly used compartmental absorption models is that they do not adequately capture the impact of intestinal physiology on systemic clearance of drugs. In the segregated gut model the intestinal compartment includes the inert serosa and the active enterocyte regions as separate compartments and the blood flow to each of these compartments is segregated (Pang et al., 2017). This is in contrast to the conventional models in which the serosa and enterocytes are considered a single well mixed compartment. Unlike traditional intestinal models where the entire intestinal blood flow perfuses the entire gut compartment, in the segregated flow model only a fraction (5-20%) of the intestinal blood flow perfuses the enterocytes (Pang et al., 2017, 2020; Noh and Pang, 2019). Since the metabolically active and drug transporter expressing component of the intestine is the enterocyte compartment this segregation of the intestinal blood flow effectively reduces the contribution of the enterocytes to the systemic clearance of drugs while maintaining the contribution of the enterocyte metabolism in first pass metabolism during drug absorption. In other words, only a fraction of the drug in arterial circulation can access the enterocyte enzymes and transporters.
allowing >80% of the drug to bypass enterocyte metabolism during systemic clearance (Pang et al., 2020). This is important in particular for intermediate to high extraction substrates of CYP3A4 and UGTs for which both intestinal and hepatic metabolism are important, but the model has also been shown to provide improved data on drug-drug interactions when both the inhibitor and substrate are administered po (Pang et al., 2020). In addition, a relatively comprehensive PBPK model of the intestine that combines the segmented gut concept allowing for simulation of enzyme and transporter expression patterns and the segregated flow concept has been developed (Pang et al., 2020). PBPK modelers should consider the segregated gut model for drugs that have relatively high clearance and are substrates for CYP3A4 or UGT enzymes.

In recent years the modeling of hepatic clearance in PBPK models has received considerable attention. In addition to number of publications in the overall hepatic clearance models for static predictions and pharmacokinetic data analysis, attention has been paid to whether the well stirred model of the liver is the most appropriate model to use in PBPK models (Li and Jusko, 2022, 2023b; a). At present commercial PBPK modeling packages as well as majority of custom made PBPK models incorporate hepatic clearance according to the well stirred model. The incorporation of the dispersion model of hepatic clearance, the most physiologically sound model of hepatic clearance (Pang and Rowland, 2019), has been computationally complex and hence limited (Li and Jusko, 2022). Instead, a series compartment liver model was incorporated into PBPK models to allow better simulation of hepatic clearance especially for high extraction ratio drugs (Watanabe et al., 2009; Li and Jusko, 2022). In the case of pravastatin, transporter contribution to the hepatic clearance was incorporated in the series compartment model and the preference for the series compartment model was justified due to the fact that dispersion model typically better captures hepatic clearance of high extraction drugs.
(pravastatin has blood flow limited hepatic clearance in rats) (Watanabe et al., 2009). The PBPK model incorporated 5 liver compartments to appropriately capture hepatic extraction of pravastatin. When the dispersion model and series compartment model results were systematically compared 1, 2 and 5 series compartments were evaluated with a goal to explore the impact of the number of series compartments in model performance (Li and Jusko, 2022). As may be expected due to added degrees of freedom in the model, adding compartments resulted in challenges in parameter identifiability and the authors concluded that it may not be trivial to define the optimal number of compartments to include (Li and Jusko, 2022). A unique advantage of the series compartment model is that it allows modeling of the zonation of enzymes within the liver. This will likely provide improvements in simulations of high extraction compounds and their metabolites. Again, PBPK modelers are encouraged to carefully consider what is the most appropriate liver model to use in model development to best capture the disposition characteristics of their drug of interest.

Renal clearance is one of the main elimination pathways for drugs and their metabolites but it has received much less attention than hepatic clearance in in vitro to in vivo predictions of drug clearance and in PBPK modeling. This is likely because renal clearance can often be well predicted via allometric scaling and/or using glomerular filtration rate (GFR) and plasma unbound fraction. Renal clearance is often included in PBPK models as simple clearance pathway without a complex physiological model of the kidney. However, allometric scaling can suffer from species differences in transporter expression, urine pH and differences in plasma protein binding (Scotcher, Jones, Posada, Galetin, et al., 2016). On the other hand, using static mechanistic modeling of renal clearance, passive reabsorption was shown to have a major impact on the accuracy of renal clearance predictions (Scotcher, Jones, Rostami-Hodjegan, et al., 2016). Of
the commercial PBPK modeling platforms Simcyp incorporates the option to use a physiologically based mechanistic kidney model (Neuhoff et al., 2013; Abduljalil, Pansari, et al., 2022) but how widely this option is used is unclear. Mechanistic modeling of the kidney in PBPK models can accurately incorporate reabsorption processes as well as active transport based on in vitro data (Huang and Isoherranen, 2018; Matsuzaki et al., 2019). An open code mechanistic kidney model was developed (Huang and Isoherranen, 2018) and incorporated into full body PBPK model (Huang et al., 2020) to predict renal clearance from in vitro data, to simulate pH dependent renal clearance and to assess urinary metabolic ratios in a parent-metabolite system. Similarly, the impact of urine frow and urine pH on renal clearance was simulated using the Simcyp mechanistic kidney model (Matsuzaki et al., 2019).

For modeling chronic kidney disease, several studies have been published in which the intact nephron hypothesis has been applied to PBPK modeling and mechanistic models of the kidney. The creatinine-drug interactions occurring between OAT2 inhibitors in different stages of kidney disease were simulated using a minimal physiologically based mechanistic kidney model (Takita et al., 2020). In a separate study a pyridoxic acid PBPK model was developed using Simcyp and the mechanistic kidney model adapted based on the intact nephron hypothesis for patients with chronic kidney disease (Tan et al., 2023). In this model the number of proximal tubular cells was decreased proportionately with GFR according to intact nephron hypothesis while the expression of OAT1/3 was decreased by additional 16%-50% from what would be proportional to GFR (Tan et al., 2023).

The assumption of intact nephron hypothesis and decrease in OAT1/3 activity in chronic kidney disease may not be appropriate in all circumstances and is likely not physiologically accurate when considered in context of tubular fluid flow (Huang and Isoherranen, 2020a).
During kidney disease the kidney undergoes adaptations to maintain the fluid balance resulting in smaller fraction reabsorbed for permeable drugs under kidney disease than in healthy kidneys (Huang and Isoherranen, 2020a). These alterations in urine and tubular flows were incorporated into a mechanistic kidney model in chronic kidney disease to predict renal clearance and the adaptation in tubular flows was shown to be necessary in modeling renal clearance changes for permeable drugs in chronic kidney disease (Huang and Isoherranen, 2020a). The decrease in OAT activity beyond what would be predicted by intact nephron hypothesis may be due to inhibition of these transporters by uremic solutes rather than additional downregulation of their expression (Chang et al., 2023). The impact of uremic solutes on kidney OAT activity and renal clearance of tenofovir in patients with renal impairment was simulated using the mechanistic kidney model (Chang et al., 2023). The importance of understanding the variability and individual changes in kidney blood flow, GFR, and transporter activity in progressive kidney disease was illustrated via use of the mechanistic kidney model to predicting drug clearance in chronic kidney disease in individual patients based on biomarker data of transporter activity in the kidney in the same individuals (Granda et al., 2023). Finally, in an effort to test whether data collected from microphysiological systems could be incorporated into PBPK models, the data of morphine and morphine glucuronide permeability and transport obtained in kidney tubule-on-a-chip model was incorporated into the mechanistic kidney model and the disposition of morphine and morphine glucuronide in patients with declining kidney function was predicted (Imaoka et al., 2021). Taken together these examples show the power of mechanistic PBPK modeling of renal clearance and the potential to translate complex in vitro data into clinical pharmacokinetic predictions and clinical pharmacology.
Distribution kinetics, predictions of plasma concentration time curves and PBPK model design

Over the past decades PBPK modeling has focused extensively on clearance predictions and different organ clearance approaches. However, one of the distinct advantages of PBPK modeling is that it allows mechanistic predictions, simulations, and analyses of distribution kinetics. Hence the shape of the plasma concentration versus time curve in addition to the area under the plasma concentration versus time curve (AUC) can be simulated based on mechanistic and preclinical data. Such predictions cannot be accomplished using compartmental models or static PK calculations without existing *in vivo* data. The complexity of predicting distribution kinetics is often overlooked in predictions of human drug disposition (Huang and Isoherranen, 2020b), and the advantages of the use of PBPK models in distribution predictions and in predicting the half-life of new compounds have not been adequately recognized. Most PBPK approaches model distribution as a perfusion limited phenomenon. However, with the acknowledgment of transporter contribution to distribution and recognized permeability limitations in distribution, PBPK models are also incorporating more complex distribution assessment. For example, recently a new PBPK model termed ‘PermQ’ was developed that incorporates permeability considerations together with intracellular lipids (Korzekwa *et al.*, 2022). This model advances the consideration for the complexity of tissue composition and capillary permeability and the simulation of distribution phenomena in and out of physiological membranes.

A typical full body PBPK model will include blood flows to the individual organs and partition coefficients (K_p values) to these organs (Figure 1). The K_p values refer to the tissue concentration (C_t) to plasma concentration (C_p) ratio at steady state (distribution equilibrium).
other words, the K_p values are the concentration ratios for a specific organ or tissue that can be measured at steady state during an iv infusion. By use of the tissue specific blood flows and K_p values, the rate and extent of distribution to these organs can be simulated and together with clearance parameters this allows simulation of the overall plasma concentration time curve.

Many methods for predicting tissue specific K_p values in silico have been published and the reader is referred to the original publications (Rodgers and Rowland, 2006; Poulin and Theil, 2009; Poulin et al., 2011) and some of the relevant reviews for more detailed analysis of this topic (Zou et al., 2012; Holt et al., 2019; Utsey et al., 2020). One limitation for the in silico methods of K_p prediction is the lack of detailed information of the composition of human tissues and organs and the still rudimentary understanding of the distribution characteristics of drugs across different cell types within an organ. For example, current prediction methods do not generally consider heterogeneity of tissues/organs with multiple different cell types nor binding to intracellular proteins such as intracellular fatty acid binding proteins that are abundant across the body and bind numerous drugs (Yabut and Isoherranen, 2023). The assumed partitioning to specific subcellular lipids (acidic, and neutral phospholipids, neutral lipids) is also typically predicted from systems such as water:octanol or water:vegetable oil partitioning that may be an inadequate reflection of the specific lipid partitioning, in particular for drugs with ionizable groups. These values are also often obtained from other in silico prediction systems that may not fully capture lipid partitioning. A note of caution should be made against the common practice of using uniform scaling factors to adjust in silico predicted K_p values to obtain a V_ss value that matches an observed V_ss or results in an apparent V_β value that allows an appropriate capture of the half-life of a drug. There is no mechanistic or scientific basis to assume that the K_p prediction from the in silico methods would be equally incorrect for all organs. For example, in the “Rodgers and
Rowland’s method the lipid composition and partitioning in each organ is considered to predict the \( K_{p,u} \) values, but the fraction of the tissue volume in the different lipid components is different and hence impacted differently for each organ (Rodgers et al., 2005). Species differences in the specific lipid content have also been noted resulting in discrepant tissue \( K_{p,u} \) predictions between species (Rodgers et al., 2012). How these differences impact extrapolation of \( K_{p,u} \) values from preclinical species to humans has not been fully elucidated and remains an area requiring further investigation. In the context of uniform scaling of \( K_p \) values, each organ has a unique and distinct effect on distribution kinetics, especially the rate of distribution, due to the different blood flows to the specific organs. It is important for the modeler to consider the scenario that a \( K_p \) error for the adipose or bone tissue will appear different in the simulation output than a similar magnitude of \( K_p \) error for the skin or muscle-two similarly sized organs.

While use of \textit{in silico} methods to predict \( K_p \) values is efficient and easy, more labor intensive and detailed experimental assessment of \( K_p \) values is recommended if the prediction of terminal half-life and distribution characteristics is desired. The predicted \( V_{ss} \) if done based on \textit{in silico} methods, also needs to be compared to some observed data. The modeler should be aware that the terminal half-life observed and simulated is dependent on CL and \( V_\beta \) rather than \( V_{ss} \) and hence accurate prediction of half-life using PBPK models requires appropriate identification of the main distribution organs that impact \( V_\beta \). This may not be obvious from simple consideration of \( V_{ss} \). In cases where active transporters are involved in distribution kinetics the permeability limited distribution processes may have a disproportionate impact on \( V_\beta \). In an ideal case, intravenous dosing data are available in humans which allows calculation of central compartment volume (\( V_c \)), \( V_{ss} \) and \( V_\beta \) but such data are rarely available to the modeler. Often iv dosing data are, however, available from preclinical species. If preclinical species data are available
following iv dosing the $V_c$ and $V_{ss}$ can be determined in preclinical species and $V_c$ and $V_{ss}$ in humans predicted using allometric scaling and the Øie-Tozer method (Øie and Tozer, 1979) that allows consideration of interspecies differences in unbound fraction in plasma. Notably, the distribution of the compound of interest to individual organs cannot be determined from plasma concentration-time curves. The determination of $V_{ss}$ even after iv dosing in humans can only provide an average $K_p$ value for all organs combined. The assignment of the $K_p$ values to specific organs is always subject to an identifiability problem. Several feasible approaches can be used in practice to acknowledge this challenge and capitalize on the power of PBPK modeling while acknowledging the lack of confidence in specific tissue $K_p$ values. As one approach, the average $K_p$ value can be calculated from $V_{ss}$ (either measured in humans or scaled from preclinical species) using the classic equation $V_{ss} = V_p + K_p \times V_T$ and all organs can initially be assigned this $K_p$. The specific $K_p$ values for some of the large organs can then be optimized (proportionally increased and decreased) to capture the terminal half-life and early distribution phase of the drug of interest without altering $V_{ss}$. The modeler can use qualitative knowledge of the lipid composition and the physicochemical characteristics of the drug to consider the most likely organs for which distribution is less or more extensive than the overall total body $K_p$ value. This approach does, however, assume that reliable clearance values are known. As an alternative approach, the $K_p$ values can be predicted using in silico methods and, as noted above, then optimized specifically to the large organs that result in detectable difference in the $V_{ss}$ prediction. In both cases it should be acknowledged that there are numerous combinations of tissue $K_p$ values that will all yield equally good plasma concentration-time curves and these values are increasingly difficult to identify following non-iv dosing routes (Huang and Isoherranen, 2020b). Similarly the more organs that are included in the model the more degrees of freedom are present.
in the model and hence the better the model fit is. As such the model generated specific tissue concentration curves should be interpreted with caution especially if the tissue concentrations are considered in light of pharmacological activity or toxicity.

Experimental measurements of $K_p$ values are beneficial for establishing specific tissue distribution characteristics. In particular, experimental verification of $K_p$ values using preclinical models is useful if a PD component is included in the model to provide additional confidence for distribution kinetics to the site of action. Additionally, if confidence is desired for the specific organs of distribution or for the rank order of $K_p$ values between tissues, experimental verification is of value. An experimentally measured $K_p$ value that is incorporated into a PBPK model should be the steady state equilibrium $C_T/C_p$ ratio. However, experimental $K_p$ values are often measured during elimination phase following iv bolus in preclinical species. The tissue to plasma concentration ratio is not the same during the elimination phase of drugs as it is at steady state (Jeong and Jusko, 2022a). This has been nicely shown via experimental studies in rats following dosing of ketamine (Edwards and Mather, 2001). The tissue to plasma concentration ratios were up to 10-fold greater during the terminal phase following iv bolus than following iv infusion. This can be explained by arteriovenous differences in concentrations of ketamine and the clearance of ketamine during the elimination phase. The arterial concentrations perfusing the tissue are lower than the venous concentrations during the elimination phase and hence the tissue becomes a reservoir for the drug. The redistribution of the drug from the tissue may be much slower than the clearance leading to a higher concentration ratio between the tissue and plasma than what would be expected from a steady state $K_p$ value. These $K_p$ values measured during the terminal elimination phase can, however, be converted to the steady state $K_p$ values for non-eliminating organs using the Chen and Gross method (Jeong and Jusko, 2022b). For eliminating
organs the clearance parameters also need to be considered and the choice of the liver model impacts the ultimate calculation of the $K_p$ value (Jeong and Jusko, 2022b; Li and Jusko, 2023b; a). As such it is important to appreciate the theoretical basis of $K_p$ values incorporated in the models and the limitations of experimentally determined concentration ratios.

Currently used criteria for model verification (AUC and $C_{\text{max}}$ fold differences) likely do not adequately explore whether distribution kinetics is appropriately described by the model and whether the shape of the plasma concentration-time curve is accurately captured. The AUC depends only on the bioavailable dose and the systemic clearance of the drug ($\text{AUC} = \text{FD/CL}$) and hence the $\text{AUC}_{\text{observed}}/\text{AUC}_{\text{predicted}}$ reflects mainly the accuracy of simulations of oral and/or systemic clearance. This lack of sensitivity of AUC to the shape of the plasma concentration curve has been previously noted and a calculation of an exposure overlap coefficient (EOC) was proposed to compare the curve shapes between simulation and observed data (Holt et al., 2019). The EOC is the calculated fraction of the observed AUC that overlaps with the predicted and hence is always a value <1. When the EOC was used to assess model performance for a series of drugs the EOC values ranged from 0.71 to 1 (Korzekwa et al., 2022). At present no clear criterion has been proposed for acceptable range for EOC for fit for purpose modeling and further assessment of this approach is needed. For EOC one may also need to consider the model fit to the observed data to allow integrations of the C versus t data and comparison of the calculated areas for the simulated concentrations. In studies where noncompartmental modeling is typically used this may require further considerations of compartmental analysis of the observed data to accurately capture the observed area of the AUC that does not overlap with the simulation.

In addition to AUC, $C_{\text{max}}$ is usually included as an additional measure to determine model performance and whether distribution and clearance parameters are defined appropriately.
C\textsubscript{max}, however, has several weaknesses as an observed parameter. First, the observed C\textsubscript{max} value depends on the sampling schedule for the observed study and can be poorly defined value if sampling is too sparse missing the true C\textsubscript{max} or if the absorption kinetics are relatively slow such as with controlled release formulations when multiple sampling points result values close to the C\textsubscript{max} and t\textsubscript{max}. Second, C\textsubscript{max} depends on multiple PK parameters and does not directly measure error in a given parameter. As such C\textsubscript{max} does not directly inform on any specific pharmacokinetic parameter and multiple parameter combinations exist to obtain C\textsubscript{max} estimates that are within acceptable range of observed data. The observed C\textsubscript{max} depends on the bioavailability (F), volume of distribution, t\textsubscript{max} and elimination rate constant k of the parent drug all of which are defined by a combination of values inputted in a PBPK model. Of particular interest for PBPK modeling is the issue of C\textsubscript{max} and the impact of V on C\textsubscript{max}. In classic pharmacokinetics following one compartment model C\textsubscript{max} is defined as

\[ C_{\text{max}} = \frac{k_a F D}{V (k_a - k)} \left[ e^{-k t_{\text{max}}} - e^{-k a t_{\text{max}}} \right] \] (Han \textit{et al.}, 2018). However, explicit solutions for C\textsubscript{max} do not exist for multicompartment models. Great majority of drugs display multicompartment behavior following iv administration and hence the interpretation of C\textsubscript{max} and error in C\textsubscript{max} simulations in PBPK models can be confounded in the absence of iv data. It should be emphasized that models of distribution kinetics can only be appropriately verified if iv data exists. In the absence of iv data PBPK models have a parameter identifiability problem; it is not possible to differentiate the effect of k\textsubscript{a}, distribution rate (\alpha in compartmental kinetics) and flip-flop phenomena and multiple possible solutions can be obtained. Such confounding effects were illustrated when comparing simulated arterial and venous concentrations and observed arterial and venous concentrations of drugs (Huang and Isoherranen, 2020b). Using buccal fentanyl as a model it was shown that the erroneous assumptions regarding distribution kinetics (comparing
observed venous to simulated arterial concentrations) could be “corrected” to yield an acceptable $C_{\text{max}}$ value by altering absorption kinetics (Huang and Isoherranen, 2020b). It should be emphasized that arteriovenous differences are specifically a distribution phenomenon and do not impact clearance which as a pharmacokinetic parameter is independent of distribution as long as true sampling is done for sufficient duration to capture terminal elimination phase and $\text{AUC}_{\text{infinity}}$.

As models become more sophisticated the evaluation of model performance and transparency in confidence in model assumptions need to keep pace. For example, it is recommended that modelers assess the overall AAPE for plasma concentration time curves in addition to the accuracy of AUC predictions to establish how well distribution kinetics is captured as AAPE allows evaluation of the entire plasma concentration-time curve. Indeed such approaches are increasingly used in published PBPK models (Table 1 and 2).

**Future Opportunities for PBPK modeling**

PBPK modeling has become a mature field within pharmaceutical sciences and the use of PBPK modeling applications has broadened to include prediction of drug disposition in variety of complex patient populations. However, incorporating the diversity of academic advances in structural model development and incorporation of more complex physiological concepts in PBPK models is becoming a challenge to commercial software platforms. It is likely that more versatility will need to be incorporated into the “closed source” or “closed code” software packages to allow modelers to explore the best structural model for the specific purpose. While software packages are moving to this direction it is still hard to predict whether the regulatory requirements of model compatibility and validation can be maintained with increased modeling
flexibility. The computational speed may also become limiting with some of these extended capabilities.

The expectations for model verification and validation have increased over the past decade and the use of independent model development datasets and model validation datasets have become well incorporated into the literature. In majority of the papers reviewed in detail for this analysis (Tables 1 and 2) the manuscripts stated a predefined acceptance criterion. Notably, many models used for specific populations were also based on previously developed models for the specific compounds in healthy volunteers. During the model development and verification process, the limitation in many cases is the ability of the modeler to identify and capture all the available clinical data for a compound of interest and to assess in a statistically rigorous way whether the model is fit for purpose in light of all available data. In addition, while the overall model may fit predefined acceptance criteria this does not mean the developed model is the best possible model for the given data. The modeler will typically go through a subjective parameter optimization process that will allow “fit-for-purpose” applications. However, in any scenario there are multiple combinations of values that will provide a model that fits the acceptance criteria. Choice of the final best fit and weight put on specific clinical and in vitro data used in model development can be subjective and yield biased data. Novel computational approaches may address this issue. Such computational approaches include artificial intelligence (AI), machine learning and artificial neural networks (ANN)(Chou and Lin, 2023). Proof of concept studies with ANNs have already been conducted and these studies have shown that ANN could predict patient plasma concentration-time curves when trained with PK data (Bräm et al., 2022). Similarly, a deep learning approach based on neural ordinary differential equations was used to predict PK data in previously unstudied scenarios (Lu et al., 2021).
For bottom-up PBPK model development most developed PBPK models already use some level of *in silico* predictions such as LopP values, pKₐ or Kₚ values although clearance predictions and permeability values still typically rely on experimental data. Machine learning methods are, however, increasingly used to generate the parameters used for PBPK model development (Chou and Lin, 2023). Machine learning is already available for many pharmacokinetic parameter predictions that have previously relied on mechanistic predictive equations (Chou and Lin, 2023) and several recent studies have incorporated AI and machine learning into PBPK modeling with AI and machine learning being used to generate specific parameters in bottom-up modeling (Chou and Lin, 2023; Chou et al., 2023; Habiballah and Reisfeld, 2023). These AI assisted PBPK models at present typically use QSAR approaches that get incorporated into the PBPK model. For example a machine learning method was developed to predict Kₚ values simply from physicochemical parameters of a drug (Chou and Lin, 2023) and the feasibility of use of machine learning methods to predict distribution characteristics was assessed in a pilot study of 12 drugs (Parrott et al., 2022).

The model development process in PBPK applications that use so called “top down” or “middle out” approach could also benefit from artificial intelligence (AI) applications and machine learning. As such one can expect that AI will become incorporated into PBPK model development workflows to allow unbiased optimization of model parameters. AI can also likely in the future significantly improve the ability of the modeler to identify and summarize all available PK data in published literature and capture the reported pharmacokinetic data. Due to the expanding computational power, machine learning and AI methods will likely also assist in evaluating multiple different model structures and rapidly provide assessment of the various
organ models, level of complexity needed for distribution modeling and assessment of critical experimental data needed to provide confidence in PBPK estimates and predictions.

In the top down and middle out approaches the modeler typically manually optimizes some parameters in the PBPK model to achieve a model that fits observed data within defined acceptance criteria. Typical parameters that are optimized include individual tissue $K_p$ values, specific enzyme intrinsic clearance values and in some cases unbound fractions, bioavailability or transporter clearance but any model parameter could theoretically be optimized. This approach is often referred to as “learn and confirm”. As noted above multiple combinations of parameters can be identified that all result in acceptable solutions that fit pre-defined acceptance criteria. A modeler often struggles in deciding how to weigh individual studies in optimization process and how to develop a model that provides the closest comprehensive match to the totality of observed clinical data. In addition, the optimization of parameters is time consuming and usually not automated relying on the knowledge and experience of the modeler to identify best parameters. It is conceivable that in the future this parameter optimization step could be done by an AI or a machine learning algorithm that samples a much greater space of possible combinations of optimized parameters and ultimately identifies the truly best model to fit to the collective clinical data available. AI applications can provide superior speed and power and enable consideration of large number of combinations of data for this purpose.

One may speculate that in the future more mechanistic models will get incorporated into the AI applications that will allow automatic optimization of the PBPK model parameters and unbiased model development and optimization within a mathematically defined framework. This will likely lead to a need to develop novel PBPK modeling platforms that interface with advanced machine learning and AI applications. It is expected that the role of the modeler will
change with these developments and there will be a need to further define how such AI generated models can be evaluated during regulatory reviews and in scientific literature.
Data Availability Statement:

The author declares that all the data supporting this review is available within the paper or through existing publications reviewed.

Authorship Contributions:

Participated in data collection: Isoherranen

Performed data analysis:Isoherranen

Wrote or contributed to the writing of the manuscript: Isoherranen


vitro to in vivo extrapolation for developmental toxicity potency of valproic acid analogues. 


Freriksen JJM, van der Heijden JEM, de Hoop-Sommen MA, Greupink R, and de Wildt SN (2023) Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines


Isoherranen N, and Thummel KE (2013) Drug metabolism and transport during pregnancy: How does drug disposition change during pregnancy and what are the mechanisms that cause such changes? *Drug Metabolism and Disposition* 41:256–262.


Yabut KCB, and Isoherranen N (2023) Impact of Intracellular Lipid Binding Proteins on Endogenous and Xenobiotic Ligand Metabolism and Disposition, NLM (Medline).


Footnotes

The author has no actual or perceived conflict of interest with the contents of this article. This work was supported in part by a grant from the National Institutes of Health [Grant P01 DA032507].
Figure captions

**Figure 1:** Representative structures of a full body PBPK model (A) and a simplified lumped compartment PBPK model (B).

**Figure 2:** Number of publications reported with PBPK modeling found in PubMed searches for the time window from 2015 to 2022. The total number of PBPK papers is shown as bar chart and the numbers of PBPK papers for select specific applications (drug-drug interactions, pediatrics, pharmacogenetics, pregnancy, and organ impairment) are shown in individual panels. The year a publication is listed is based on when the manuscript first appeared in PubMed (if ahead of print).
### Tables

Table 1. Summary of PBPK models published in 2022 for organ impairment applications. N/A not available

<table>
<thead>
<tr>
<th>Drug/Imatinib</th>
<th>Application</th>
<th>Model structure</th>
<th>CL prediction</th>
<th>V prediction</th>
<th>Population description</th>
<th>Verification/validation</th>
<th>Acceptance criterion</th>
<th>Software</th>
<th>PMID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acalabrutinib and metabolite ACP-5862</td>
<td>BTK occupancy PD (PBPK-BO)</td>
<td>Full PBPK</td>
<td>Bottom up</td>
<td>Rodgers &amp; Rowland</td>
<td>Healthy, HI</td>
<td>Independent studies, DDI</td>
<td>Fold error</td>
<td>PK-Sim</td>
<td>(L. Xu et al., 2022)</td>
</tr>
<tr>
<td>Alprazolam, sirolimus, nifedipine, midazolam, felodipine, buspirone, ibrutinib</td>
<td>Hepatic impairment and CYP3A4 activity</td>
<td>Minimal and full PBPK</td>
<td>SimCYP library files with adjustment</td>
<td>SimCYP library files with adjustment</td>
<td>Matched to observed, HI</td>
<td>SimCYP library files with adjustment, iv and po data</td>
<td>2-fold for PK parameters</td>
<td>SimCYP</td>
<td>(Ladumor et al., 2023)</td>
</tr>
<tr>
<td>Baricitinib Tofacitinib</td>
<td>Covid19, geriatric, RI</td>
<td>Minimal PBPK</td>
<td>Published models, SimCYP library</td>
<td>Published models, SimCYP library</td>
<td>Similar to observed</td>
<td>Previous studies, multiple populations</td>
<td>1.84-fold AUCR</td>
<td>SimCYP</td>
<td>(Wang and Chan, 2022b)</td>
</tr>
<tr>
<td>Bexarotene</td>
<td>Prospective prediction of PK in AKI and different stages of CKD</td>
<td>Full PBPK</td>
<td>Middle out, scaling and in vivo PK</td>
<td>Scaled to humans from rats</td>
<td>Demographics consistent with observed data, cancer population</td>
<td>Sensitivity analysis,</td>
<td>AFE within 2 or 3 fold, 95% predictive intervals</td>
<td>PK-Sim</td>
<td>(Alsmadi and Alzughoul, 2023)</td>
</tr>
<tr>
<td>Ciprofloxacin, furosemide, meropenem, acyclovir</td>
<td>OAT expression in CKD</td>
<td>Full PBPK</td>
<td>Bottom up (OATs, MATE, MRP, CYP, UGT)</td>
<td>Rodgers &amp; Rowland</td>
<td>Healthy RI</td>
<td>Independent studies, DDI</td>
<td>AFE 07-1,3, AAFE &lt;2, 85-95% of observed within 90th pred interval</td>
<td>PK-Sim</td>
<td>(Dubinsky et al., 2022)</td>
</tr>
<tr>
<td>Dorzagliatin</td>
<td>Prospective prediction of RI</td>
<td>N/A</td>
<td>IVIVE</td>
<td>Allometric scaling</td>
<td>Healthy, T2DM</td>
<td>Independent studies, DDI</td>
<td>N/A</td>
<td>SimCYP</td>
<td>(Miao et al., 2022)</td>
</tr>
<tr>
<td>Esaxerenone</td>
<td>Hepatic impairment</td>
<td>Minimal PBPK</td>
<td>In vivo PK</td>
<td>In vivo</td>
<td>Matched to clinical</td>
<td>Independent studies, DDI</td>
<td>DDI ratio</td>
<td>SimCYP</td>
<td>(Watanabe et al., 2022)</td>
</tr>
<tr>
<td>Febuxostat</td>
<td>Renal impairment</td>
<td>Full PBPK</td>
<td>In vivo</td>
<td>Rodgers-Single</td>
<td>Healthy, gout patients</td>
<td>Independent studies, gout patients</td>
<td>% error</td>
<td>GastroPlus</td>
<td>(Y Xu et al., 2022)</td>
</tr>
<tr>
<td>Janagliflozin</td>
<td>Renal impairment, Hepatic impairment</td>
<td>Full PBPK</td>
<td>PBPK from rat and dog and enzyme</td>
<td>PBPK from rat and dog</td>
<td>Similar to observed, renal and hepatic impairment</td>
<td>Healthy individuals, T2DM HI and RI studies</td>
<td>2-fold for fold change</td>
<td>GastroPlus</td>
<td>(Zhao et al., 2022)</td>
</tr>
<tr>
<td></td>
<td>levels in humans</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>---------------------------------</td>
<td>---------------</td>
<td>-----------------------------------</td>
<td>----------</td>
<td>----------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Remdesivir</strong></td>
<td>Predict hepatic and renal</td>
<td>Full PBPK</td>
<td>Middle out</td>
<td>Rodgers</td>
<td>Similar to</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolites</td>
<td>impairment, tissue PK of</td>
<td></td>
<td></td>
<td>and Rowland</td>
<td>observed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>remdesivir</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Rivaroxaban</strong></td>
<td>Disease-drug interaction, PD</td>
<td>Minimal PBPK</td>
<td>Library</td>
<td>Library</td>
<td>Prospective</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>or Warfarin</td>
<td>(INR)</td>
<td></td>
<td></td>
<td></td>
<td>healthy,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>with ritonavir</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>white</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Geriatric</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CKD,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>moderate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>impairment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tacrolimus</strong></td>
<td>Renal and hepatic impairment</td>
<td>Minimal PBPK</td>
<td>Bottom-up with ISEF</td>
<td>In vivo data</td>
<td>CYP3A5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>genotyped</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>similar population(s)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>healthy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Trelagliptin</strong></td>
<td>DPP4 occupancy, RI</td>
<td>Full PBPK</td>
<td>GFR</td>
<td>Rodgers and Rowland</td>
<td>Genotyped</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oarigliptin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>studies,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>healthy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Treprostinil</strong></td>
<td>Extended release in</td>
<td>Full PBPK</td>
<td>In vivo, top down retrograde</td>
<td>Rodgers and Rowland</td>
<td>Independent</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatic impairment</td>
<td></td>
<td></td>
<td></td>
<td>studies (iv, po)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>% error</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;50%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(DFan et al., 2022)

(Wang and Chan, 2022a)

(IItohara et al., 2022)

(C Wu et al., 2022)

(X Wu et al., 2022)
<table>
<thead>
<tr>
<th>Drug</th>
<th>Application</th>
<th>Model structure</th>
<th>CL prediction</th>
<th>V prediction</th>
<th>Population description</th>
<th>Verification/validation</th>
<th>Acceptance criterion</th>
<th>Software</th>
<th>PMID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefazolin, Cefuroxime, Amoxicillin</td>
<td>Maternal-fetal concentrations. PK in pregnancy, placental and fetal exposure</td>
<td>fullPBPK with fetoplacental model</td>
<td>Mechanistic kidney model</td>
<td>Full PBPK model, Rodgers and Rowland method for Kp</td>
<td>Pregnant and nonpregnant matched demographics or default</td>
<td>N/A</td>
<td>Simcyp</td>
<td>(Abduljali, Ning, et al., 2022)</td>
<td></td>
</tr>
<tr>
<td>Acyclovir, Emtricitabine, Lamivudine, Metformin</td>
<td>Maternal-fetal concentrations. PK in pregnancy, placental and fetal exposure</td>
<td>fullPBPK with fetoplacental model</td>
<td>Mechanistic kidney model</td>
<td>Full PBPK model, Rodgers and Rowland method for Kp with scaling</td>
<td>N/A</td>
<td>Prior models for nonpregnant used except lamivudine. Predicted compared to observed</td>
<td>Simcyp</td>
<td>(Abduljali, Pansari, et al., 2022)</td>
<td></td>
</tr>
<tr>
<td>Ampicillin</td>
<td>Fetal and neonatal ampicillin concentrations for Streptococcus infection treatment</td>
<td>fullPBPK with fetoplacental model</td>
<td>Top down (retrograde) for liver and biliary Mechanistic kidney model for CLr</td>
<td>Full PBPK model, Rodgers and Rowland method for Kp</td>
<td>Matched to observed</td>
<td>FDA guidance workflow for healthy adults and pediatrics</td>
<td>Observed within the 95th and 5th percentiles of predicted; predicted within twofold of the observed</td>
<td>Simcyp</td>
<td>(Li and Xie, 2023)</td>
</tr>
<tr>
<td>Ritonavir boosted lopinavir, chloroquine, ivermectin</td>
<td>Population drug-drug interactions for COVID including special populations</td>
<td>fullPBPK</td>
<td>Previously published and middle out, enzyme kinetics</td>
<td>Additional protein binding prediction for special populations. Poulin and Theil or Rodgers and Rowland prediction of Kp</td>
<td>Similar to observed, 1:1 male to female. The original PK-Sim pregnancy population was customized to include enzyme changes</td>
<td>Historical PPK data in nonpregnant populations</td>
<td>At least 85% of the observed data within the 90% predictive interval, Sensitivity analysis</td>
<td>PK-Sim</td>
<td>(Alsmadi, 2023)</td>
</tr>
<tr>
<td>Doravirine</td>
<td>Predict maternal and fetal</td>
<td>Full PBPK</td>
<td>Previously developed</td>
<td>Optimized from prior model. Nonpregnant individuals</td>
<td>Independent data following iv and po predicted/observed ratios for</td>
<td>Simcyp</td>
<td></td>
<td></td>
<td>(Bukkems et al., 2022)</td>
</tr>
<tr>
<td>Chemical/Drug</td>
<td>Action</td>
<td>Methodology</td>
<td>Units</td>
<td>Prior Work</td>
<td>Description</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>--------</td>
<td>-------------</td>
<td>-------</td>
<td>------------</td>
<td>-------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General (859 chemicals with human toxicokinetic data)</td>
<td>Predict fetal exposure for toxicokinetics</td>
<td>Placental perfusion studies for fetal distribution</td>
<td>AUC, C&lt;sub&gt;max&lt;/sub&gt;, and C&lt;sub&gt;trough&lt;/sub&gt; between 0.7 and 1.3</td>
<td>From prior work</td>
<td>Maternal-to-fetal plasma ratio at birth</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remdesivir and its GS-704277 and GS-441524 metabolites</td>
<td>Translate prior nonpregnant model to pregnancy</td>
<td>Measured partition coefficient when available. Prior models</td>
<td>N/A</td>
<td>N/A</td>
<td>R (Kapraun et al., 2022)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ceftazidime, cefuroxime, metformin, oseltamivir, amoxicillin</td>
<td>Assess assessment of PBPK for renally cleared drugs during pregnancy</td>
<td>Matched to observed</td>
<td>Previously published nonpregnant model, observed data in pregnancy</td>
<td>AUC, C&lt;sub&gt;max&lt;/sub&gt;, and C&lt;sub&gt;24&lt;/sub&gt; within 2-fold</td>
<td>PK-Sim with MoBi (Liu et al., 2023)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-gp and BCRP transported drugs, nelfinavir, efavirenz, imatinib</td>
<td>Fetal-to-maternal unbound steady state plasma concentration ratio</td>
<td>Full PBPK with Kp predicted using Poulin and Theil method (N)</td>
<td>Independently validated in nonpregnant subjects. IV and PO dosing data. Efavirenz and imatinib previously developed and validated for nonpregnant</td>
<td>N/A</td>
<td>Simcyp (Peng et al., 2022)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valproic acid</td>
<td>Predict developmental toxicity of valproic acid</td>
<td>Simulated concentrations compared to toxicologically relevant concentrations</td>
<td>N/A</td>
<td>N/A</td>
<td>R, Gastroplus (Chang et al., 2022)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>